Patents by Inventor Shirishkumar Kulkarni
Shirishkumar Kulkarni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11278502Abstract: The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.Type: GrantFiled: September 28, 2018Date of Patent: March 22, 2022Assignee: LUPIN LIMITEDInventors: Shirishkumar Kulkarni, Satish Kumar Dalal, Harshal Jahagirdar, Kishore Kumar Konda
-
Publication number: 20200375959Abstract: A solid dispersion of rifaximin comprising rifaximin and pharmaceutically acceptable carrier. A pharmaceutical composition comprising the solid dispersion of rifaximin.Type: ApplicationFiled: May 6, 2020Publication date: December 3, 2020Applicant: Lupin LimitedInventors: Shirishkumar KULKARNI, Satish Kumar DALAL, Harshal Anil JAHAGIRDAR
-
Patent number: 10842802Abstract: The present disclosure provides novel controlled release pharmaceutical dosage form, methods of making the same, and methods of using the same to treat dermatological conditions.Type: GrantFiled: May 8, 2013Date of Patent: November 24, 2020Assignee: MEDICIS PHARMACEUTICAL CORPORATIONInventors: Sajeev Chandran, Shirishkumar Kulkarni, Pravin Meghrajji Bhutada, Ashish Ashokrao Deshmukh, Douglas Bakan, Mitchell Wortzman
-
Patent number: 10786464Abstract: The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.Type: GrantFiled: November 3, 2010Date of Patent: September 29, 2020Assignee: LUPIN LIMITEDInventors: Shirishkumar Kulkarni, Satish Kumar Dalal, Harshal Jahagirdar, Kishore Kumar Konda
-
Publication number: 20190192490Abstract: A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.Type: ApplicationFiled: November 26, 2018Publication date: June 27, 2019Applicant: Lupin Limited ( Research Park)Inventors: Harshal Anil Jahagirdar, Kishore Kumar Konda, Satish Kumar Dalal, Shirishkumar Kulkarni
-
Publication number: 20190076536Abstract: A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract.Type: ApplicationFiled: April 2, 2018Publication date: March 14, 2019Applicant: LUPIN LIMITEDInventors: Harshal Anil JAHAGIRDAR, Rajesh KULKARNI, Shirishkumar KULKARNI
-
Publication number: 20190029968Abstract: The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.Type: ApplicationFiled: September 28, 2018Publication date: January 31, 2019Applicant: LUPIN LIMITEDInventors: Shirishkumar Kulkarni, Satish Kumar Dalal, Harshal Jahagirdar, Kishore Kumar Konda
-
Patent number: 10137114Abstract: A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.Type: GrantFiled: November 10, 2015Date of Patent: November 27, 2018Assignee: LUPIN LIMITEDInventors: Harshal Anil Jahagirdar, Kishore Kumar Konda, Satish Kumar Dalal, Shirishkumar Kulkarni
-
Patent number: 9931405Abstract: A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract.Type: GrantFiled: February 2, 2015Date of Patent: April 3, 2018Assignee: LUPIN LTD.Inventors: Harshal Anil Jahagirdar, Rajesh Kulkarni, Shirishkumar Kulkarni
-
Patent number: 9884022Abstract: A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean Tmax of tapentadol is reached after 10 hours of administration of the composition. The composition comprises tapentadol, such that it maintains serum concentration of tapentadol of at least about 20 ng/ml for at least about 17 hours after oral administration of the composition. According to one embodiment the controlled release pharmaceutical composition comprises tapentadol, which is gastroretentive.Type: GrantFiled: February 7, 2011Date of Patent: February 6, 2018Assignee: LUPIN LIMITEDInventors: Ashish Ashokrao Deshmukh, Pravin Meghrajji Bhutada, Sajeev Chandran, Shirishkumar Kulkarni
-
Patent number: 9820936Abstract: The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria.Type: GrantFiled: July 12, 2016Date of Patent: November 21, 2017Assignee: LUPIN LIMITEDInventors: Ashish Ashokrao Deshmukh, Pravin Meghrajji Bhutada, Sajeev Chandran, Shirishkumar Kulkarni
-
Publication number: 20170027863Abstract: The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria.Type: ApplicationFiled: July 12, 2016Publication date: February 2, 2017Inventors: Ashish Ashokrao DESHMUKH, Pravin Meghrajji BHUTADA, Sajeev CHANDRAN, Shirishkumar KULKARNI
-
Patent number: 9421165Abstract: The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria.Type: GrantFiled: February 3, 2012Date of Patent: August 23, 2016Assignee: LUPIN LIMITEDInventors: Ashish Ashokrao Deshmukh, Pravin Meghrajji Bhutada, Sajeev Chandran, Shirishkumar Kulkarni
-
Publication number: 20160136141Abstract: A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.Type: ApplicationFiled: November 10, 2015Publication date: May 19, 2016Applicant: LUPIN LIMITEDInventors: Harshal Anil JAHAGIRDAR, Kishore Kumar KONDA, Satish Kumar DALAL, Shirishkumar KULKARNI
-
Patent number: 9211258Abstract: A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.Type: GrantFiled: March 9, 2011Date of Patent: December 15, 2015Assignee: LUPIN LIMITEDInventors: Harshal Anil Jahagirdar, Kishore Kumar Konda, Satish Kumar Dalal, Shirishkumar Kulkarni
-
Publication number: 20150343070Abstract: A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract.Type: ApplicationFiled: February 2, 2015Publication date: December 3, 2015Inventors: Harshal Anil JAHAGIRDAR, Rajesh KULKARNI, Shirishkumar KULKARNI
-
Patent number: 9040089Abstract: A taste masked pharmaceutical composition of clindamycin, or a pharmaceutically acceptable salt(s), hydrate(s), solvate(s) and physiologically functional derivative(s) and precursors thereof, which includes all polymorphic forms, whether crystalline or amorphous comprising polyhydric alcohol(s); and one or more other pharmaceutically acceptable excipient(s). A process for preparation of a taste masked pharmaceutical composition of clindamycin or a pharmaceutically acceptable salt(s) thereof the said process comprising the steps of a) dry mixing clindamycin, polyhydric alcohol and other pharmaceutically acceptable excipient(s) to get a dry mixture; b) granulating the dry mixture above with a granulating liquid prepared by mixing the suitable pharmaceutically acceptable excipient(s) with aqueous/non-aqueous fluid to obtain a wet mass; c) drying the wet mass to obtain the discrete particles; d) lubricating the discrete particles obtained with a suitable lubricating agent and/or flavor(s).Type: GrantFiled: September 10, 2008Date of Patent: May 26, 2015Assignee: LUPIN LIMITEDInventors: Kalpana Walzade, Rajesh Kulkarni, Shirishkumar Kulkarni
-
Patent number: 8974825Abstract: A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract.Type: GrantFiled: June 24, 2008Date of Patent: March 10, 2015Assignee: Lupin LimitedInventors: Harshal Anil Jahagirdar, Rajesh Kulkarni, Shirishkumar Kulkarni
-
Publication number: 20150017242Abstract: The present invention relates to multi component composition of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of multi component composition of Dronedarone would improve the bioavailability and the patient compliance with reduction in number of dosages to be taken per day.Type: ApplicationFiled: February 14, 2013Publication date: January 15, 2015Inventors: Ashish Ashokrao Deshmukh, Hemant Bhalerao, Pravin Meghrajji Bhutada, Sajeev Chandran, Shirishkumar Kulkarni
-
Patent number: 8916194Abstract: A controlled release pharmaceutical compositions comprising Milnacipran or pharmaceutically acceptable salts thereof is provided. The pharmaceutical composition comprises an immediate release core comprising Milnacipran or pharmaceutically acceptable salts thereof, pharmaceutically acceptable excipients and a coating on the immediate release core comprising rate controlling agents.Type: GrantFiled: August 26, 2011Date of Patent: December 23, 2014Assignee: Lupin LimitedInventors: Shirishkumar Kulkarni, Rajesh Kulkarni, Pandharinath Jadhav, Ashish Tiwari